Bengster like most ultra smart retailer has been playing a poker game with everyone.  Now I think he is either secretly collecting (if BIG's inner secrets are known to him) or having sold everything and staying away (If BIG presents no potentials for future price spikes.)

To those who are innocently invested like me, I must say.  Look at your own positions.  If you are overall ok with your finances, stay put, no buy and no sell.  Keep what you have and don't like AK go in to average, because unless we are some insiders who know the dark truth, we might get stuck for some time.  The only hope for us will be a takeover of BIG by some good foresighted concerns who are willing to pay the price of goodwill in BIG's vast researches into heart problems and method logics of its stents.

It will surely happen.

For BIG, revenue is more important than profitability as it position itself as a acquisition target.

The following 2 paragraphs are extracted from OCBC Research :

Market share vs. profitability.

Biosensors' gross margins have and will continue to improve due to 1) sales increase in high margin DES products; 2) better optimisation in balancing direct sales force vs. distributors and; 3)greater efficiencies from its operations. We continue to adhere to our stance that Biosensors will fixate on gaining market share (growing revenue) in the near term vs. cutting costs to attain profitability. This is to gain elevated market presence and to eventually position itself for an acquisition.

Good company, but better target.

While we agree that Biosensors has breakthrough technology, we are mindful that the medtech world continually sees consolidation. As an acquisition target, significant accretion to an acquirer's market share and technology pipeline outweighs profitability concerns. Although details were lacking due to competitive reasons, management updated that its next-gen BioMatrix-Freedom polymer-free DES continues to garner good feedback. Our checks in the US Patent database shows Biosensors' Freedom stent patent was filed on 21 May 2007.

 Note : The guidance (regarding profitability) given in late 2007 is no longer valid due to the failed JWMS deal.